New combo aims to wipe out hidden leukemia before transplant
NCT ID NCT07443488
First seen Mar 10, 2026 · Last updated May 13, 2026 · Updated 10 times
Summary
This study tests whether a combination of two drugs (olverembatinib and inotuzumab ozogamicin) can eliminate leftover leukemia cells in adults with a certain type of acute lymphoblastic leukemia (Ph+ ALL) who still have detectable disease after initial treatment. The goal is to achieve a deep remission before proceeding to a stem cell transplant. About 20 participants will be enrolled in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HSCT are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.